GoodRx Appoints Raj Beri as Chief Operating Officer, Mark Hull as Chief Product Officer and Vina Leite as Chief People Officer

$GDRX
EDP Services
Technology
Get the next $GDRX alert in real time by email

The company bolsters its leadership team with experienced mission-driven executives

GoodRx (NASDAQ:GDRX), a leading consumer-focused digital healthcare platform, today announced it has made key leadership appointments to support the company's scaling business and accelerate innovation to bring more affordable and convenient healthcare to consumers across the country.

Raj Beri will join GoodRx as the company's first ever Chief Operating Officer (COO) from Uber, where he served as Vice President of Grocery and New Verticals, overseeing the company's non-restaurant and last mile delivery businesses across global markets. With more than 20 years in the business operations space, Raj will lead continued growth and expansion at GoodRx, while helping increase value across the prescriptions business.

"GoodRx has seen tremendous growth over the past few years and I am eager to help lead the company through the next phase of its evolution as part of this innovative leadership team," said Beri. "I'm passionate about working on audacious problems across sectors that are ripe for disruption, and GoodRx is at the center of that disruption in the healthcare industry."

In addition, Mark Hull has been named the first ever Chief Product Officer to help the company build industry-leading solutions for consumers, providers and pharmacists. Previously a senior product executive at Meta and LinkedIn, Mark will draw on his more than 25 years of experience in the product management industry to make GoodRx more accessible, convenient and useful for consumers, while helping scale opportunities with partners.

Vina Leite has joined GoodRx as the company's first Chief People Officer. With expertise in the global human resources and talent management space, Vina brings more than two decades of experience in transforming high-growth and Fortune 500 organizations. Vina will support growth at GoodRx by helping to develop scalable people operations functions while hiring and developing top talent in an environment that is empowered by diversity, equity and inclusion.

The company also welcomes Scott Paul as Senior Vice President of Healthcare & Consumer Innovation. Scott will leverage his substantial healthcare experience and knowledge to work with senior leadership on all areas of healthcare innovation across the ecosystem of consumers, retailers, PBMs, providers and drug manufacturers. Scott previously founded Apex Affinity, where he created and ran many of the largest pharmacy discount programs in the market, and most recently served as Executive Vice President at MedImpact, where he focused primarily on consumer savings and digital health.

"As GoodRx continues on our rapid growth trajectory, we're thrilled to welcome these mission-driven additions to our leadership team," said Doug Hirsch, co-CEO and co-founder of GoodRx. "Raj, Mark, Vina and Scott are innovative, forward-thinking executives who believe in GoodRx's vision and core values. Their deep experience and expertise across consumer-driven, B2B and healthcare industries will be invaluable to GoodRx as we continue to help millions of consumers access affordable and convenient healthcare."

Andrew Slutsky will transition to a new role at the company, driving new initiatives as Senior Vice President of Strategy & Marketing Innovation.

About GoodRx

GoodRx is a leading consumer-focused digital healthcare platform. Our technology delivers strong savings, trusted information and access to care to make healthcare affordable and convenient for all Americans. Since 2011, we have helped consumers save over $35 billion and are one of the most downloaded medical apps over the past decade.

Forward-Looking Statement

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements contained in this press release that do not relate to matters of historical fact should be considered forward-looking statements, including without limitation statements regarding our future operations, growth and financial results and the benefits of new hires. These statements are neither promises nor guarantees, but involve known and unknown risks, uncertainties and other important factors that may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements, including, but not limited to, the satisfaction of the closing conditions of the vitaCare acquisition, risks associated with acquired businesses, including risks related to our limited operating history and early stage of growth; our ability to achieve broad market education and change consumer purchasing habits; our ability to continue to attract, acquire and retain consumers in a cost-effective manner; our reliance on our prescription transactions offering and ability to expand our offerings; changes in medication pricing and pricing structures; our inability to control the categories and types of prescriptions for which we can offer savings or discounted prices; our reliance on a limited number of industry participants; the competitive nature of industry; our ability to attract, develop, motivate and retain well-qualified employees; and the other important factors discussed under the caption "Risk Factors" in GoodRx's Annual Report on Form 10-K for the year ended December 31, 2021, and our other filings with the SEC. These factors could cause actual results to differ materially from those indicated by the forward-looking statements made in this press release. Any such forward-looking statements represent management's estimates as of the date of this press release. While we may elect to update such forward-looking statements at some point in the future, we disclaim any obligation to do so, even if subsequent events cause our views to change.

Get the next $GDRX alert in real time by email

Chat with this insight

Save time and jump to the most important pieces.

Recent Analyst Ratings for
$GDRX

DatePrice TargetRatingAnalyst
12/4/2024$5.00Neutral
Mizuho
8/9/2024$10.00Outperform → Strong Buy
Raymond James
5/23/2024$8.00 → $10.00Sector Perform → Outperform
RBC Capital Mkts
5/16/2024$10.00Mkt Perform → Outperform
Raymond James
4/10/2024$9.00Sector Weight → Overweight
KeyBanc Capital Markets
3/25/2024$7.50 → $10.00Equal Weight → Overweight
Wells Fargo
3/1/2024$7.00 → $10.00Neutral → Overweight
JP Morgan
2/26/2024$8.00Outperform
Leerink Partners
More analyst ratings

$GDRX
Press Releases

Fastest customizable press release news feed in the world

See more
  • GoodRx Appoints Aaron Crittenden as President of Rx Marketplace and Scott Pope, PharmD, as Chief Pharmacy Officer and Head of Clinical Engagement

    Accomplished healthcare executives will work to drive growth, strengthen industry partnerships, and enhance pharmacy innovation at GoodRx GoodRx (NASDAQ:GDRX), the leading platform for medication savings in the U.S., today announced the appointment of Aaron Crittenden as President of Rx Marketplace and Scott Pope, PharmD, as Chief Pharmacy Officer and Head of Clinical Engagement, effective immediately. Aaron will be responsible for the management and financial performance of GoodRx's Rx Marketplace offering, working with key retail pharmacy, pharmacy benefit manager (PBM), employer, and manufacturer partners. He will also play a critical role in shaping GoodRx's long-term growth strategy

    $GDRX
    EDP Services
    Technology
  • GoodRx Report Reveals Striking Gender Divide in Prescription Medication Spending

    Women Spent $8.8 Billion More than Men in 2024, with Women Ages 18-44 Facing the Steepest Out-of-Pocket Cost Disparity GoodRx (NASDAQ:GDRX), the leading platform for medication savings in the U.S., today released a new report, The Prescription Drug Gender Divide, detailing how women shoulder a significantly greater out-of-pocket cost burden than men. The data shows that in 2024, women spent $8.8 billion – or 30% – more than men on out-of-pocket prescription costs. Combined with the common responsibilities of managing a career, family planning, and caregiving, women are left frustrated with the financial pressure required to maintain their health. Though the "pink tax" is often thought abo

    $GDRX
    EDP Services
    Technology
  • GoodRx Reports Fourth Quarter and Full Year 2024 Results

    Fourth Quarter and Full Year 2024 Results Substantially In-line with Previous Guidance GoodRx Holdings, Inc. (NASDAQ:GDRX) ("we," "us," "our," "GoodRx," or the "Company"), the leading prescription savings platform in the U.S., has released its financial results for the fourth quarter and full year of 2024. Fourth Quarter 2024 Highlights Revenue1 of $198.6 million Net income of $6.7 million; Net income margin of 3.4% Adjusted Net Income1 of $34.7 million; Adjusted Net Income Margin1 of 17.5% Adjusted EBITDA1 of $67.1 million; Adjusted EBITDA Margin1 of 33.8% Net cash provided by operating activities of $44.7 million Exited the quarter with over 7 million consumers of pr

    $GDRX
    EDP Services
    Technology

$GDRX
Analyst Ratings

Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

See more

$GDRX
Insider Purchases

Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

See more

$GDRX
Insider Trading

Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

See more

$GDRX
SEC Filings

See more

$GDRX
Leadership Updates

Live Leadership Updates

See more
  • GoodRx Appoints Aaron Crittenden as President of Rx Marketplace and Scott Pope, PharmD, as Chief Pharmacy Officer and Head of Clinical Engagement

    Accomplished healthcare executives will work to drive growth, strengthen industry partnerships, and enhance pharmacy innovation at GoodRx GoodRx (NASDAQ:GDRX), the leading platform for medication savings in the U.S., today announced the appointment of Aaron Crittenden as President of Rx Marketplace and Scott Pope, PharmD, as Chief Pharmacy Officer and Head of Clinical Engagement, effective immediately. Aaron will be responsible for the management and financial performance of GoodRx's Rx Marketplace offering, working with key retail pharmacy, pharmacy benefit manager (PBM), employer, and manufacturer partners. He will also play a critical role in shaping GoodRx's long-term growth strategy

    $GDRX
    EDP Services
    Technology
  • GoodRx Appoints Christopher A. McGinnis as Chief Financial Officer

    Seasoned industry executive brings decades of financial strategy and leadership experience to GoodRx GoodRx (NASDAQ:GDRX), the leading prescription savings platform in the U.S., today announced that Christopher A. McGinnis has been appointed as Chief Financial Officer, effective February 4, 2025. Chris brings 30 years of extensive financial experience across the healthcare industry to his new role. Chris will join GoodRx following his role as CEO of CitizensRx, where he led the company in providing pharmacy benefit management services to commercial clients. Before that, Chris held various executive roles at Lumeris / Essence Healthcare, a Medicare Advantage plan and value-based healthca

    $GDRX
    EDP Services
    Technology
  • WM Technology, Inc. Names Sarah Griffis Chief Technology Officer

    WM Technology, Inc. ("WM Technology" or the "Company") (NASDAQ:MAPS), a leading marketplace and technology solutions provider to the cannabis industry, today announced the appointment of Sarah Griffis as the Company's new Chief Technology Officer, effective January 6, 2025. "I am thrilled to welcome Sarah as our new CTO. She has great experience not just building and leading engineering and tech teams, but also operating in regulated industries like ours," said Doug Francis, Chief Executive Officer at Weedmaps. "I look forward to partnering with her and the rest of our tech org to continue delivering innovative and best-in-class technology solutions to our customers." Prior to joining W

    $GDRX
    $MAPS
    EDP Services
    Technology
    Computer Software: Prepackaged Software

$GDRX
Financials

Live finance-specific insights

See more
  • GoodRx Reports Fourth Quarter and Full Year 2024 Results

    Fourth Quarter and Full Year 2024 Results Substantially In-line with Previous Guidance GoodRx Holdings, Inc. (NASDAQ:GDRX) ("we," "us," "our," "GoodRx," or the "Company"), the leading prescription savings platform in the U.S., has released its financial results for the fourth quarter and full year of 2024. Fourth Quarter 2024 Highlights Revenue1 of $198.6 million Net income of $6.7 million; Net income margin of 3.4% Adjusted Net Income1 of $34.7 million; Adjusted Net Income Margin1 of 17.5% Adjusted EBITDA1 of $67.1 million; Adjusted EBITDA Margin1 of 33.8% Net cash provided by operating activities of $44.7 million Exited the quarter with over 7 million consumers of pr

    $GDRX
    EDP Services
    Technology
  • GoodRx Announces Date for Fourth Quarter and Full Year 2024 Earnings Release and Conference Call

    GoodRx Holdings, Inc. (NASDAQ:GDRX) ("GoodRx" or the "Company"), the leading prescription savings platform in the U.S., today announced it will release its fourth quarter and full year 2024 financial results before U.S. markets open on Thursday, February 27, 2025. GoodRx management will also hold a conference call and webcast that morning at 5:00 a.m. Pacific Time (8:00 a.m. Eastern Time) to discuss the results and the Company's business outlook. To access the conference call, please pre-register using this link. Registrants will receive a confirmation with dial-in details and a unique passcode required to join. The call will also be webcast live on the Company's investor relations websit

    $GDRX
    EDP Services
    Technology
  • GoodRx Reports Third Quarter 2024 Results

    GoodRx Holdings, Inc. (NASDAQ:GDRX) ("we," "us," "our," "GoodRx," or the "Company"), the leading prescription savings platform in the U.S., has released its financial results for the third quarter of 2024. Third Quarter 2024 Highlights Revenue1 and Adjusted Revenue1 of $195.3 million Net income of $4.0 million; Net income margin of 2.0% Adjusted Net Income1 of $31.9 million; Adjusted Net Income Margin1 of 16.4% Adjusted EBITDA1 of $65.0 million; Adjusted EBITDA Margin1 of 33.3% Net cash provided by operating activities of $86.9 million Exited the quarter with over 7 million consumers of prescription-related offerings2 "In a world where there is increasing attention on medicin

    $GDRX
    EDP Services
    Technology

$GDRX
Large Ownership Changes

This live feed shows all institutional transactions in real time.

See more